Relmada Therapeutics Inc (RLMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2016 | 06-2015 | 06-2014 | 12-2013 | 06-2013 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -2,975 | -20,804 | -21,336 | -19,872 | N/A |
| Depreciation Amortization | 55 | 9 | 409 | 189 | N/A |
| Accounts receivable | -232 | N/A | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | 424 | 89 | 566 | -57 | N/A |
| Other Working Capital | 1,678 | -1,120 | 480 | 419 | N/A |
| Other Operating Activity | -12,094 | 5,598 | 17,717 | 17,084 | 0 |
| Operating Cash Flow | $-13,144 | $-16,227 | $-2,164 | $-2,238 | $N/A |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -562 | -23 | -4 | -9 | N/A |
| Investing Cash Flow | $-562 | $-23 | $-4 | $-9 | $N/A |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | N/A | 502 | N/A |
| Common Stock Issued | N/A | 13,424 | 22,229 | N/A | N/A |
| Other Financing Activity | -264 | -268 | 1,981 | 3,494 | 0 |
| Financing Cash Flow | $-264 | $13,156 | $24,210 | $3,996 | $N/A |
| Beginning Cash Position | 22,470 | 25,564 | 3,523 | 1,773 | N/A |
| End Cash Position | 8,500 | 22,470 | 25,564 | 3,523 | N/A |
| Net Cash Flow | $-13,970 | $-3,094 | $22,042 | $1,750 | $N/A |
| Free Cash Flow | |||||
| Operating Cash Flow | -13,144 | -16,227 | -2,164 | -2,238 | N/A |
| Capital Expenditure | -562 | -23 | -4 | -9 | N/A |
| Free Cash Flow | -13,706 | -16,250 | -2,168 | -2,246 | 0 |